A historical ICU comparison found more intensive sedation in COVID-ARDS, while shorter stays could not be interpreted as faster recovery.
What the source reports
Among 150 ventilated adults in one hospital during 2021, 112 had COVID-ARDS. They generally received deeper and more often multidrug sedation, with higher daily midazolam and propofol doses. Their recorded ventilation and hospitalization durations were shorter, but mortality was 100%, compared with 89.47% in the non-COVID group.
Limits and uncertainty
Retrospective treatment selection, severity differences and the extraordinary mortality restrict causal conclusions. Death can shorten length of stay and ventilation duration. Associations between combinations and vasopressor-requiring shock had very wide confidence intervals and cannot isolate a specific medicine from disease severity.
Implications for forensic review
For ICU outcome interpretation, check why observation ended before describing a shorter duration as a benefit. Reconstruct respiratory support, sedation goals, prone positioning and shock. This cohort illustrates competing outcomes and confounding; it does not show that higher midazolam doses caused either shorter treatment or the observed mortality.
Source and related reading
Source reviewed: Sedation Practices for Intubated Patients with COVID 19 and non COVID 19 Acute Respiratory Distress (PMC13013552). Forensic applications above are interpretive analysis of the supplied paper.
Related reading: Early Korean COVID Cohort Did Not Find a Significant Benzodiazepine Mortality Association.
Leave a Reply